In a significant advancement for metastatic colorectal cancer (mCRC) patients with BRAF V600E mutations, Pfizer’s targeted therapy Braftovi® (encorafenib) has demonstrated remarkable efficacy in combination with cetuximab and chemotherapy. Recent Phase 3 BREAKWATER trial results…
Highlighted by Hong Kong DengYue Medicine What is Ensacove Ensartinib? Ensacove Ensartinib (X-396) is an advanced second-generation ALK tyrosine kinase inhibitor (TKI) designed to treat patients with ALK-positive non-small cell lung cancer (NSCLC). Developed to…
The U.S. Food and Drug Administration (FDA) has approved Crenessity™ (crinecerfont) as an adjunctive treatment to glucocorticoid therapy for adults and children aged four years and older with classic congenital adrenal hyperplasia (CAH) due to…
In a significant advancement for hemophilia care, the U.S. Food and Drug Administration (FDA) has approved Alhemo® (concizumab-mtci) as a once-daily prophylactic treatment for adults and children aged 12 years and older with hemophilia A…
In a significant advancement for retinal disease management, the U.S. Food and Drug Administration (FDA) has approved Beovu® (brolucizumab-dbll) 6 mg for the treatment of diabetic macular edema (DME). This marks the second FDA-approved indication…
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the official U.S. launch of Tryngolza™ (olezarsen), a novel, once-monthly RNA-targeted therapy for familial chylomicronemia syndrome (FCS). The drug enters the market at an annual list price of…
In 2025, Sanofi’s Cablivi (caplacizumab-yhdp) continues to play a pivotal role in the management of acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening blood disorder. As the first FDA-approved nanobody therapy for aTTP, Cablivi…
Lybalvi (olanzapine/samidorphan), a new antipsychotic drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with schizophrenia and bipolar I disorder, has been formally launched in the U.S. recently. The…
The U.S. Food and Drug Administration (FDA) has approved a novel targeted drug, Lytgobi (Futibatinib), for the treatment of unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA) patients. This approval provides a new treatment option…
March 2025 Knight Therapeutics announced that its anti-CD19 monoclonal antibody drug Minjuvi (tafasitamab) has been officially marketed in Mexico. For the treatment of adult patients who are not candidates for autologous hematopoietic stem cell transplantation…
Migraines afflict more than one billion people worldwide, and their attacks of severe headache, light sensitivity and nausea often bring patients’ lives to a halt. In 2020, the FDA approved Nurtec ODT (rimegepant).This orally dissolvable…
In recent years, Testosterone Replacement Therapy (TRT) has become one of the hotspots in the global healthcare market as men’s health issues have become a growing concern. Among them, Nebido (Testosterone Undecanoate), as a long-acting…
